Inhibikase Therapeutics (IKT) Common Equity (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Common Equity of $153.33 million for Q2 2026, up 91.5% from $80.05 million a year earlier but down 8.5% from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Common Equity (2020 - 2026) Analysis & Trends
At the end of FY2025, Inhibikase Therapeutics posted Common Equity of $172.9 million, up 82.3% from FY2024.
- Common Equity has a five-year compound annual growth rate of 77.6% (FY2020 to FY2025).
- By year, Common Equity came in at $94.87 million in FY2024 (+764.2%), $10.98 million in FY2023 (-47.8%), $21.04 million in FY2022 (-45.2%) and $38.42 million in FY2021 (+292.6%).
- Five-year quarterly Common Equity spans a low of -$530,591 in Q3 2024 and a high of $172.9 million in Q4 2025.
- Year over year, Common Equity has now increased in each of the last three quarters, with growth averaging 258.4% over the last four quarters.
- The high point for year-over-year Common Equity in five years was Q4 2024 (growth of 764.2%); the low point was Q2 2024 (a decline of 73.8%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $167.62 million (Q1 2026), $172.9 million (Q4 2025) and $72.9 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Inhibikase Therapeutics | 357.87 Mn | -227.60 Mn | - | 153.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 153.33 Mn |
| Mar 31, 2026 | 167.62 Mn |
| Dec 31, 2025 | 172.90 Mn |
| Sep 30, 2025 | 72.90 Mn |
| Jun 30, 2025 | 80.05 Mn |
| Mar 31, 2025 | 85.73 Mn |
| Dec 31, 2024 | 94.87 Mn |
| Sep 30, 2024 | -530,591.00 |
| Jun 30, 2024 | 5.10 Mn |
| Mar 31, 2024 | 6.78 Mn |
| Dec 31, 2023 | 10.98 Mn |
| Sep 30, 2023 | 15.02 Mn |
| Jun 30, 2023 | 19.46 Mn |
| Mar 31, 2023 | 25.28 Mn |
| Dec 31, 2022 | 21.04 Mn |
| Sep 30, 2022 | 25.14 Mn |
| Jun 30, 2022 | 29.50 Mn |
| Mar 31, 2022 | 34.01 Mn |
| Dec 31, 2021 | 38.42 Mn |
| Sep 30, 2021 | 43.16 Mn |
API Access
Inhibikase Therapeutics Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();